FDA warns Novo Nordisk over unreported potential Ozempic side effects

The Food and Drug Administration (FDA) has issued a warning letter to Novo Nordisk, citing concerns over unreported potential side effects related to its medications Ozempic and Wegovy. The Danish drugmaker, which produces the popular diabetes and weight-loss drugs, is now under scrutiny regarding its compliance with regulatory reporting standards. This action by the FDA indicates a focus on pharmaceutical transparency and patient safety concerning widely prescribed medications. The warning letter could prompt further investigations or require Novo Nordisk to take corrective actions regarding its reporting practices.